Olverembatinib is named as an intervention in 14 current clinical trials in our China, UK, USA and India registers. 12 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Institute of Hematology & Blood Diseases Hospital, China (5). The most-studied condition is Chronic Myeloid Leukemia.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409 · ClinicalTrials.gov ↗ · Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
|
Phase 3 | Recruiting | Ascentage Pharma Group Inc. | UK, USA, China |
|
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911 · ClinicalTrials.gov ↗ · Chronic Myeloid Leukemia, CML, CML, Chronic Phase
|
Phase 3 | Recruiting | Ascentage Pharma Group Inc. | UK, USA, India |
|
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
NCT07152041 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic
|
Phase 3 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | China |
|
Olverembatinib for FGFR1-rearranged Neoplasms
NCT05521204 · ClinicalTrials.gov ↗ · Myeloproliferative Neoplasm, Acute Leukemia
|
Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | China |
|
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
NCT04501120 · ClinicalTrials.gov ↗ · Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy
|
Phase 1/2 | Recruiting | Ascentage Pharma Group Inc. | China |
|
Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia
NCT06082934 · ClinicalTrials.gov ↗ · Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia
|
Phase 1/2 | Recruiting | Xijing Hospital | China |
|
Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML
NCT06757855 · ClinicalTrials.gov ↗ · CML,Blast Phase
|
Phase 1/2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | China |
|
Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment
NCT07282093 · ClinicalTrials.gov ↗ · Pharmacokinetic, Olverembatinib
|
Phase 1 | Recruiting | Ascentage Pharma Group Inc. | China |
|
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
NCT06390306 · ClinicalTrials.gov ↗ · Chronic Myeloid Leukemia
|
Observational | Recruiting | Peking University People's Hospital | China |
|
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
NCT06481228 · ClinicalTrials.gov ↗ · Philadelphia Positive Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult
|
Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | China |
|
ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
NCT07454226 · ClinicalTrials.gov ↗ · Ph-Like, Acute Lymphoblastic Leukemia
|
Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | China |
|
Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL
NCT07493161 · ClinicalTrials.gov ↗ · Ph+ ALL
|
Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | China |
|
A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL
NCT05931757 · ClinicalTrials.gov ↗ · Philadelphia-Positive ALL
|
Phase 2 | Not yet open | The First Affiliated Hospital of Soochow University | China |
|
Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase
NCT07383298 · ClinicalTrials.gov ↗ · Chronic Myeloid Leukemia
|
Observational | By invitation | Qian Jiang | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Chronic Myeloid Leukemia | 3 |
| Ph+ ALL | 2 |
| Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | 1 |
| CML | 1 |
| CML, Chronic Phase | 1 |
| Relapsed/Refractory Acute Myeloid Leukaemia | 1 |
| Myeloid Malignancy | 1 |
| Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) | 1 |
| Childhood Leukemia, Acute Lymphoblastic | 1 |
| Philadelphia-Positive ALL | 1 |
| Pharmacokinetic | 1 |
| Olverembatinib | 1 |
| Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia | 1 |
| Philadelphia Positive Acute Lymphoblastic Leukemia | 1 |
| Acute Lymphoblastic Leukemia, Adult | 1 |
| Ph-Like | 1 |
| Acute Lymphoblastic Leukemia | 1 |
| CML,Blast Phase | 1 |
| Myeloproliferative Neoplasm | 1 |
| Acute Leukemia | 1 |
| Lead sponsor | Trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 5 |
| Ascentage Pharma Group Inc. | 4 |
| The First Affiliated Hospital of Soochow University | 2 |
| Xijing Hospital | 1 |
| Peking University People's Hospital | 1 |
| Qian Jiang | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 13 | 11 |
| Clinical trials in UK | 2 | 2 |
| Clinical trials in USA | 2 | 2 |
| Clinical trials in India | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
14 current trials in our China, UK, USA and India registers name Olverembatinib as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 12 of the 14 trials are recruiting: 11 with sites in China, 2 with sites in UK, 2 with sites in USA and 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Institute of Hematology & Blood Diseases Hospital, China (5), Ascentage Pharma Group Inc (4), The First Affiliated Hospital of Soochow University (2) and Xijing Hospital (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Olverembatinib works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Olverembatinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Olverembatinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.